A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes-Reference-Cited by-同舟云学术

A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes

Published:2019-08-08 Issue:11 Volume:21 Page:2496-2504
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Halvorsen Yuan‐Di C.¹^ORCID,Walford Geoffrey A.¹,Massaro Joseph²,Aftring Robert P.³,Freeman Mason W.¹^ORCID

Affiliation:

1. Translational Medicine Group, Center for Computational and Integrative BiologyMassachusetts General Hospital Boston Massachusetts

2. Department of Biostatistics, Mathematics and StatisticsBoston University Boston Massachusetts

3. Theracos, Inc. Marlborough Massachusetts

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13833

Reference26 articles.

1. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

2. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

3. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

4. Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

5. Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Treatment of Diabetes Mellitus: An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus;Journal of Endocrinology and Metabolism;2024-06

2. Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry;2024-04

3. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial;Journal of Diabetes;2024-04

4. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-03-26

5. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials;Clinical Research in Cardiology;2024-02-14